Published in Arthritis Rheum on August 01, 2010
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) (2012) 6.51
Inhibition of the catalytic function of activation-induced cytidine deaminase promotes apoptosis of germinal center B cells in BXD2 mice. Arthritis Rheum (2011) 2.33
Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis (2012) 1.61
The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) (2015) 1.54
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
B-cell targeted therapeutics in clinical development. Arthritis Res Ther (2013) 1.09
Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther (2013) 1.07
B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol (2012) 1.05
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther (2013) 0.99
B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol (2013) 0.97
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther (2011) 0.93
B-cell-depleting therapy in systemic lupus erythematosus. Am J Med (2012) 0.90
Preventing autoimmunity protects against the development of hypertension and renal injury. Hypertension (2014) 0.90
Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp Immunol (2012) 0.89
Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov Med (2010) 0.87
Pathogenesis and targeted treatment of skin injury in SLE. Nat Rev Rheumatol (2015) 0.86
The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord (2014) 0.86
B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford) (2012) 0.85
Rituximab: wanted dead or alive... Arthritis Rheum (2010) 0.84
Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus. Autoimmune Dis (2012) 0.83
In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med (2014) 0.83
Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review. Clin Rheumatol (2016) 0.82
Available evidence and outcome of off-label use of rituximab in clinical practice. Eur J Clin Pharmacol (2013) 0.82
B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol (2011) 0.82
Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. J Zhejiang Univ Sci B (2012) 0.82
Oral mucosal involvement in bullous lupus. Arthritis Rheum (2013) 0.81
Early-onset neutropenia induced by rituximab in a patient with lupus nephritis and hemolytic anemia. Case Rep Rheumatol (2015) 0.81
Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr (2015) 0.81
Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther (2010) 0.80
Belimumab in systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis (2012) 0.80
Biological therapy in systemic lupus erythematosus. Int J Rheumatol (2012) 0.80
Clearing the complexity: immune complexes and their treatment in lupus nephritis. Int J Nephrol Renovasc Dis (2011) 0.79
Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol (2016) 0.79
Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int (2014) 0.78
Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians. Clin Exp Nephrol (2011) 0.78
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. Arthritis Res Ther (2016) 0.78
Lupus: an overview of the disease and management options. P T (2012) 0.78
Pediatric lupus nephritis: Management update. World J Nephrol (2014) 0.77
Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. Ther Adv Musculoskelet Dis (2015) 0.77
Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol (2015) 0.77
Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature. Lupus (2013) 0.77
Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int (2011) 0.76
Systemic lupus erythematosus: a therapeutic challenge for the XXI century. Clin Rheumatol (2014) 0.76
B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab. Biologics (2012) 0.75
Ofatumumab treatment in lupus nephritis patients. Clin Kidney J (2016) 0.75
New treatment options for lupus - a focus on belimumab. Ther Clin Risk Manag (2012) 0.75
Current and emerging treatment options in the management of lupus. Immunotargets Ther (2016) 0.75
Recent advances in the treatment of lupus nephritis. Clin Exp Nephrol (2011) 0.75
Therapy: Off-label biologics use and infection risk-the great unknown. Nat Rev Rheumatol (2011) 0.75
Immunomodulatory drugs: oral and systemic adverse effects. Med Oral Patol Oral Cir Bucal (2014) 0.75
Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. Clin Rheumatol (2014) 0.75
Overview of pathophysiology and treatment of human lupus nephritis. Curr Opin Rheumatol (2016) 0.75
Rituximab in the treatment of severe lupus myelopathy. Clin Rheumatol (2011) 0.75
Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol (2017) 0.75
Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther (2017) 0.75
[Established medications : new areas of application]. Z Rheumatol (2013) 0.75
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One (2017) 0.75
[In Process Citation]. Wien Med Wochenschr (2014) 0.75
The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. Clin Rheumatol (2015) 0.75
Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore) (2017) 0.75
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med (2008) 13.87
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity (2009) 9.01
Comparison of registered and published primary outcomes in randomized controlled trials. JAMA (2009) 7.89
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med (2002) 7.52
A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J (2003) 6.88
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med (2014) 5.98
Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation (2010) 5.87
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
The DRESS syndrome: a literature review. Am J Med (2011) 5.13
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet (2002) 4.84
Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA (2010) 4.56
Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39
Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med (2009) 4.19
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood (2012) 3.96
Public availability of results of trials assessing cancer drugs in the United States. J Clin Oncol (2013) 3.73
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 3.64
Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments. Ann Intern Med (2008) 3.63
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum (2002) 3.55
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood (2012) 3.44
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr (2008) 3.44
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum (2005) 3.44
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37
Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study. PLoS Med (2012) 3.33
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis (2009) 3.28
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis (2013) 3.25
Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med (2007) 3.18
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 3.14
Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A (2006) 3.11
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis (2013) 2.99
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis (2010) 2.91
The systemic capillary leak syndrome: a case series of 28 patients from a European registry. Ann Intern Med (2011) 2.88
Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J (2005) 2.83
Quality of reporting of noninferiority and equivalence randomized trials. JAMA (2006) 2.79
Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) (2009) 2.73
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis (2010) 2.71
Leiomyosarcoma of the inferior vena cava: experience in 22 cases. Ann Surg (2006) 2.65
Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann Intern Med (2011) 2.62
CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood (2011) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med (2014) 2.54
Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) (2004) 2.54
Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med (2010) 2.52
What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J (2007) 2.52
Comparison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures. Ann Surg (2014) 2.48
Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum (2004) 2.44
Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum (2008) 2.41
Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol (2014) 2.40
Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol (2012) 2.38
Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med (2014) 2.36
The immune paradox of sarcoidosis and regulatory T cells. J Exp Med (2006) 2.35
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol (2005) 2.35
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum (2013) 2.28
Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) (2004) 2.27
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 2.22